logo-loader
/**/ sup{font-size:80%}h1{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Helvetica Neue";color:#365F91;border:none;font-weight:normal;}h2{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:9.8pt;margin-bottom:.0001pt;text-align:center;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #000000 }visited{ color: fuchsia } .cv{size:596.0pt 843.0pt;margin:65.65pt 58.0pt 56.75pt 54.0pt;}div.cv{}p.ff{margin-top:2.2pt;margin-right:23.5pt;margin-bottom:0cm;margin-left:27.75pt;margin-bottom:.0001pt;text-align:center;font-size:14.0pt;font-family:"Calibri","sans-serif";color:black;border:none;font-weight:bold;margin-top:0cm;margin-right:23.5pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt}span.fd{font-size:11.0pt}p.fg{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;margin-right: 23.45pt; text-align: center}p.fh{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;font-weight: bold; margin-bottom: 0cm; margin-left: 27.75pt; margin-right: 23.45pt; margin-top: 0cm; text-align: center}p.fi{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;text-align:justify;text-justify:inter-ideograph; border:none}strong.ey{font-div: italic}span.ez{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black;font-weight:normal}p.fj{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify;text-justify:inter-ideograph} span.ew{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.fk{font-family:"Calibri","sans-serif";color:windowtext;color:black}span.ev{color:black}p.cd,li.cd,div.cd{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}span.et{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}table.fl{width:466.0pt;margin-left:-5.4pt;border-collapse:collapse}tr.ej{height:25.5pt}td.eq{width:60.2pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt}p.fm{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;border: none; font-weight: bold; text-align: center}span.es{border: none; font-family: "Arial","sans-serif"; font-size: 10.0pt} td.eo{width:56.2pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt}span.ep{border:none}td.en{width:24.2pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt}td.em{width:69.2pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt}td.el{width:35.2pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt}td.ek{width:54.2pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt}tr.ea{height:12.75pt}td.eh{width:60.2pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}p.fn{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;border:none}td.ef{width:56.2pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt} p.fo{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;border: none; text-align: right}td.ee{width:24.2pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.ed{width:69.2pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.ec{width:35.2pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}td.eb{width:54.2pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt}p.fp{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.dy{font-size: 11.0pt;font-family:"Calibri","sans-serif"}span.dw{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}p.fq{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:-1.0cm;margin-bottom:.0001pt;text-indent:1.0cm}span.dv{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black} p.fr{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;margin-left:-10.35pt;text-indent:10.35pt}span.dt{border: none; font-family: "Calibri","sans-serif"; font-size: 11.0pt}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;}p.fs{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; text-justify:inter-ideograph}span.ft{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.dp{font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: center}p.fu{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;font-weight: bold}p.n,li.n,div.n{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;}table.fv{margin-left:-10.8pt;border-collapse:collapse}td.dm{width:209.75pt;padding:0cm 5.4pt 0cm 5.4pt} p.fw{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;font-weight: bold}span.dn{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}td.dj{width:258.05pt;padding:0cm 5.4pt 0cm 5.4pt}p.fx{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;text-align: right}span.dl{font-size:11.0pt; font-family:"Calibri","sans-serif";color:blue}p.fy{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;font-div: italic; font-weight: bold}span.dh{font-size:11.0pt;font-family:"Helvetica Neue"}span.dg{font-size:11.0pt;font-family:"Calibri","sans-serif";background:white}span.df{font-size:11.0pt;font-family: "Calibri","sans-serif";color:blue;background:white}span.de{font-size:11.0pt;font-family:"Calibri","sans-serif"; background:white} p.db{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-justify: inter-ideograph}span.dc{font-size:11.0pt;font-family: "Calibri","sans-serif";border:none}p.fz{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt}p.ga{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;text-align:justify;text-justify:inter-ideograph}span.cz{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:#0066CC}span.cy{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:#1F497D}p.gb{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; text-justify:inter-ideograph}span.gc{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.gd{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; text-justify:inter-ideograph}span.ge{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black} p.bi,li.bi,div.bi{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;font-size:10.0pt;font-family:"Times New Roman","serif";color:#1F497D;} /**/
RNS Number : 1349C
Shield Therapeutics PLC
13 June 2019
 

Shield Therapeutics plc

("Shield" or the "Group")

 

Result of 2019 Annual General Meeting

 

London, UK, 13th June 2019:        Shield Therapeutics plc (LSE:STX), a commercial stage, specialty pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces the results of the proxy vote for each of the resolutions set out in the Notice of AGM.

The following table shows the votes cast on each resolution:


VOTES
FOR

%

VOTES
AGAINST

%

VOTES
TOTAL

% of ISC VOTED

VOTES
WITHHELD

1

91,099,593

99.16

769,230

0.84

91,868,823

78.46%

0

2

86,706,679

94.40

5,144,503

5.60

91,851,182

78.45%

17,641

3

91,079,163

99.14

789,611

0.86

91,868,774

78.46%

49

4

86,767,461

94.45

5,101,313

5.55

91,868,774

78.46%

49

5

91,868,823

100.00

0

0.00

91,868,823

78.46%

0

6

85,998,231

93.61

5,870,543

6.39

91,868,774

78.46%

49

7

91,065,998

99.14

790,943

0.86

91,856,941

78.45%

11,882

8

91,835,228

99.97

29,777

0.03

91,865,005

78.46%

3,818

9

74,183,338

80.76

17,677,421

19.24

91,860,759

78.45%

8,064

10

74,179,520

80.76

17,677,421

19.24

91,856,941

78.45%

11,882

11

17,401,749

18.94

74,455,192

81.06

91,856,941

78.45%

11,882

12

91,856,941

100.00

0

0.00

91,856,941

78.45%

11,882

 

The Board reports that resolutions 1 to 9 passed as ordinary resolutions and resolutions 10 and 12 were passed as special resolutions. Special resolution 11 was not passed, however resolutions 9 and 10 were obtained which authorise the Company to allot equity share capital including the right to issue up to 5% of issued share capital disapplying pre-emption rights.

 

Notes

1.   Percentage of shares voted: 78.46% (Number of shares in issue 117,088,657).  

2.   Details of the votes received on the resolutions are available on the Company's website: https://www.shieldtherapeutics.com/investors/corporate-documents/.

3.   Shield Therapeutics plc LEI: 213800G74QWY15FC3W71

 

 

- Ends -

 

For further information please contact:

 

Shield Therapeutics plc

www.shieldtherapeutics.com

Carl Sterritt, Chief Executive Officer

+44 (0)20 7186 8500

Tim Watts, Chief Financial Officer




Nominated Advisor and Broker


Peel Hunt LLP


James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

 



Joint Broker


finnCap Ltd

+44 (0)20 7220 0500

Geoff Nash /Matt Radley/ Alice Lane                                    

 

 

Walbrook PR

+44 (0)20 7933 8780 or [email protected]

Paul McManus / Helen Cresswell

+44 (0)7980 541 893 / +44 (0)7841 917 679

 

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs.  The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.  Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019.  For more information please visit www.shieldtherapeutics.com. 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGCKNDDNBKDQAD

Quick facts: Shield Therapeutics PLC

Price: 184.5

Market: LSE
Market Cap: £216.21 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics: Analyst discusses further positive data from...

Proactive Research analyst Emma Ulker discusses further positive data which has been released from Shield Therapeutics' (LON:STX) non-inferiority AEGIS H2H study. It pitted Shield's oral ferric maltol (branded as Feraccru in Europe and Accrufer in US) against intravenous ferric carboxymaltose...

3 weeks, 2 days ago